

Attorney Docket: 01834CIP/HG

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

# 5

Applicant(s): Takeshi IMANISHI et al.

Serial No. : 10/054,300

Filed: January 22, 2002

For : NOVEL BICYCLONUCLEOSIDE

ANALOGUES

Art Unit : 1646

Examiner

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Express Mail Mailing Label
No.: EV 075 593 470 US
Date of Deposit: April 19, 2002
I hereby certify that this paper is being deposited with the United States Postal
Service "Express Mail Post Office to
Addressee" service with sufficient postage under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231

Melissa Marks

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee, or any other fee required in connection with this Paper to Account No. 06-1378.

## SIR:

The present application is a CIP of International Application No. PCT/JP00/04902.

Submitted concomitantly herewith are the following:

- (1) Forms PTO/SB/08A and PTO/SB/08B;
- (2) A copy of the International Search Report for PCT/JP00/04902;
- (3) Copies of the publications cited in said International Search Report (WO 98/39352 and <u>Tett. Letters</u>, <u>40</u>, 6465-6468 (1999));
- (4) Copies of other publications which are cited on said Forms PTO/SB/08A and PTO/SB/08B; and
- (5) A copy of copending related application Serial No. 09/925,673, filed August 9, 2001.

WO 98/39352, which is listed in the International Search Report for PCT/JP00/04902 is also discussed on page 2 of the present specification.



The enclosed copy of the International Search

The enclosed copy of the International Search Report is in English.

It is respectfully requested that the attached publications be considered and made "of record".

Respectfully submitted,

AECENTER 1800/29

RICHARD S. BARTH REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN, LANGER & CHICK, P.C. 767 THIRD AVENUE - 25TH FLOOR NEW YORK, NEW YORK 10017-2023 Tel. No. (212) 319-4900 Fax No. (212) 319-5101

RSB/ddf

14

Enclosures: (1) Forms PTO/SB/08A and PTO/SB/08B

- (2) Publications identified on said Forms PTO/SB/08A and PTO/SB/08B
- (3) A copy of International Search Report for PCT/JP00/04902, dated October 10, 2000
- (4) A copy of copending related application Serial No. 09/925,673, filed August 9, 2001

Attorney Docket: 01834CIP/HG

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Takeshi IMANISHI et al.

erial No. : 10/054,300

9 2007 Filed : January 22, 2002

: NOVEL BICYCLONUCLEOSIDE

ANALOGUES

Art Unit : 1646

Examiner :

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

copending related application Serial No.

09/925,673, filed August 9, 2001; and

PTO/SB/08A (08-00)

U.S. Patent and Trademar	k Office: U.S. DEPARTMENT OF COMMERCE
Application Number	10/054,300
Filing Date	January 22, 2002
First Named Inventor	Takeshi IMANISHI
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	01834CIP/HG
	Application Number  Filing Date  First Named Inventor  Group Art Unit  Examiner Name

#### U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No¹	Document Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
		09/925,673		KANEKO et al.		
	:	3,687,808		MERIGAN, Jr. et al.	08-29-1972	
		4,689,320		KAJI	08-25-1987	
		4,806,463		GOODCHILD et al.	02-21-1989	
		5,514,577		DRAPER et al.	05-07-1996	
		5,661,134		COOK et al.	08-26-1997	
		5,004,810		DRAPER	04-02-1991	
		5,166,195		ECKER	11-24-1992	
	ĺ	5,194,428		AGRAWAL et al.	03-16-1993	
		5,242,906		PAGANO et al.	09-07-1993	
		5,248,670		DRAPER et al.	09-28-1993	
		5,442,049		ANDERSON et al.	08-15-1995	
		5,457,189		CROOKE et al.	10-10-1995	
		5,514,577		DRAPER et al.	05-07-1996	
		5,523,389		ECKER et al.	06-04-1996	
		5,580,767		COWSERT et al.	12-03-1996	
		5,582,972		LIMA et al.	12-10-1996	
		5,582,986		MONIA et al.	12-10-1996	
- 17		5,591,600		ECKER	01-07-1997	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Place a check here if English translation is attached.

		MATERIAL OF COMMERCE
Substitute for Form 1449A/PTO	Application Number	10/054,300
	Filing Date	January 22, 2002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Takeshi IMANISHI
APR 1 9 2002	Group Art Unit	1646
	Examiner Name	
Sheet 2	Attorney Docket Number	01834CIP/HG

## U.S. PATENT DOCUMENTS

Exam. Inits*	Cite No¹	Document Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
		5,591,623		BENNETT et al.	01-07-1997	
		5,591,720		ANDERSON et al.	01-07-1997	
		5,607,923		COOK et al.	03-04-1997	
		5,620,963		COOK et al.	04-15-1997	
		5,658,891	i	DRAPER et al.	08-19-1997	
		5,661,134		COOK et al.	08-26-1997	
		5,681,747		BOGGS et al.	10-28-1997	
		5,681,944		CROOKE et al.	10-28-1997	
		5,691,461		ECKER et al.	11-25-1997	
		5,877,309		McKAY et al.	03-02-1999	
		5,955,443		BENNETT et al.	09-21-1999	
	ľ	5,985,558		DEAN et al.	11-16-1999	
		6,111,094		BENNETT et al.	08-29-2000	
		6,127,533		COOK et al.	10-03-2000	

## FOREIGN PATENT DOCUMENTS

Exam Inits	Cite No¹	Offc <sup>3</sup>	Offc' Document Number'		Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T <sup>6</sup>
		WIPO	WO 94/08003		MONIA et al.	04-14-1994		
		WIPO	WO 96/31557		JACOBSEN	10-10-1996		
		WIPO	WO 98/39352		IMANISHI	09-11-1998		
Examine	Examiner			<del></del>	Date			•

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPBP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

DATE MAILED: April 19, 2002

Signature

<sup>&#</sup>x27;Unique citation designation number. 'See kinds of U.S. Patent Documents.' Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.' Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 'Place a check here if English translation is attached.

		I						
Substitute	for Form 1449A/PTO	Application Number	10/054,300					
		Filing Date	January 22, 2002					
INFORMATION STATEMENT I	DISCLOSURE PE	First Named Inventor	Takeshi IMANISHI					
	APR 1 9 2002	Group Art Unit	1646					
		Examiner Name						
Sheet 3	OF CLASSICAL PROPERTY OF THE PARTY OF THE PA	Attorney Docket Number	01834CIP/HG					
	OTHER PRIOR ART	- NON-PATENT LITERATU	RE DOCUMENTS					
Examiner Ci Initials No	te Include name of author page(s), volume-issu	(in CAPITAL LETTERS), title of e number(s), publisher, city and	article, title of item, date, d/or country where published T2					
	Expression Precedes Derm	"Keratinocyte Intercellular Add al T Lymphocytic Infiltration in J. Pathology, 1989, 135, 1045-10	n Allergic Contact Dermatitis					
		ence-Specific Recognition and Mo , <u>Angew. Chem. Int. Ed. Engl.</u> , 1						
		mically Modified Oligonucleotide national Edition, 1991, 30, 613						
		cal Modifications to Improve Upt es", <u>Ann. N.Y. Acad. Sci.</u> , 1992,						
		, "Tumor Cell Interactions with stasis", <u>Annu. Rev. Cell Biol.</u> ,						
	COOK, "Medicinal chemist Cancer Drug Design, 1991		s- future opportunities", <u>Anti-</u>					
	LoVo DX Cell Line Is Pro	MORASSUTTI et al., "Reduction of mdr1 Gene Amplification in Human Multidrug-Resistant LoVo DX Cell Line Is Promoted by Triple Helix-Forming Oligonucleotides", Antisense & Nucleic Acid Drug Development, 1999, 9, 261-270.						
	Antisense Oligonucleotid B. Lebleu, CRC Press, 19	SANGHVI, "Heterocyclic Base Modifications in Nucleic Acids and their Applications in Antisense Oligonucleotides", Antisense Research and Applications, Ed. S.T. Crooke and B. Lebleu, CRC Press, 1993, 273-288 (Chapter 15).						
	SHIOHARA et al., "Fixed	Drug Eruption", <u>Arch. Dermatol.</u>	, 1989, 125, 1371-1412.					
Examiner Signature		Date Considered						
			<del></del>					

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Place a check here if English translation is attached.

Substitute fo	r Form 1449A/PTO	Application Number	10/054,300	
		Filing Date	January 22, 2002	
INFORMATION D STATEMENT BY		First Named Inventor	Takeshi IMANISHI	
	4 np 1 9 2002	Group Art Unit	1646	
	Arn	Examiner Name		
Sheet 4	oly To	Attorney Docket Number	01834CIP/HG	
	OTHER PRIOR ART	- NON-PATENT LITERATU	RE DOCUMENTS	
Examiner Cite Initials No. 1		(in CAPITAL LETTERS), title of e number(s), publisher, city and		T²
		bition of Transcription Elongati cted Covalent Modification of th 619-628.		
		tion of Gene Expression and Cell otides Directed to the <i>c-myc</i> Gen		
		leishmanicidal effect of phosph -mediated delivery", <u>Biochimica</u>		
		bition of HIV proliferation in M ed to lipophilic groups", <u>Biochi</u>		
		duction of a lipophilic thioethe isense applications", <u>Bioorganic</u> 770.		:
		c Acid-Oligonucleotide Conjugate hemistry Letters, 1994, 4, 1053-		
		ibition of PCR by Non-Extendable ent DNA Polymerase", <u>Biotechniqu</u>		
		ular adhesion molecule-I (ICAM-I Dermatol., 1989, 120, 479-484.	expression correlated to	
)	TAM and FRASER-REID, "A : 1979, 57, 2818-2822.	synthetic route to 4-C-methyl-xy	rlo-furanose", <u>Can. J. Chem.</u> ,	
Examiner Signature		Date Considered		

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Place a check here if English translation is attached.

						· · · · · · · · · · · · · · · · · · ·		
Substitut	Substitute for Form 1449A/PTO		Application	on Number	10/054,300			
			·	Filing Dat	ce	January 22, 2002		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Name	ed Inventor	Takeshi IMANISHI		
	>,	* 3005 ES		Group Art	Unit	1646		
	APR 1			Examiner 1	Name			
Sheet	STENT.	of	10	Attorney I	Docket Number	01834CIP/HG		
		OTHER P	RIOR ART	- NON-PAT	TENT LITERAT	URE DOCUMENTS		
	Cite No.¹					article, title of item, date, d/or country where published	T²	
			e growth fact			mor growth by expression of Cancer Immunol. Immunother.,		
			"Prospects fo on, 1996, 14(		utic Use of Antige	ne Oligonucleotides", <u>Cancer</u>		
		like Growth	Factor-1 (IG	F-1) Receptor		Antisense RNA to the Insulin- c and Induce Regression of		
			Plasmid to th			genesis by an Antisense Receptor", <u>Cancer Research</u> ,		
						se 9 Expression by a Ribozyme <u>r Research</u> , 1996, 56, 5279-		
			•	ucleophilic D 968, 8, 82-88	-	ons in Carbohydrates",		
		selectin, P	BOGGEMEYER et al., "Borrelia Burgdorferi Upregulates the Adhesion Molecules E-selectin, P-selectin, ICAM-1 and VCAM-1 on Mouse Endothelioma Cells in vitro", Cell Adhesion and Communication, 1994, 2, 145-157.					
		KERR et al., "TGF- $\beta$ 1 Inhibition of Transin/Stromelysin Gene Expression is Mediated through a Fos Binding Sequence", Cell, 1990, 61, 267-278.						
				ed nucleic ac <u>un.</u> , 1998, 4,		d high-affinity nucleic acid		
Examiner Signature					Date Considered			

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $<sup>^{1}</sup>$  Unique citation designation number.  $^{2}$  Place a check here if English translation is attached.

Substitu	te fo	r Form 1449	9A/PTO	Application	on Number	10/054,300		
				Filing Dat	ce	January 22, 2002		
	APR 1 9 2002				ed Inventor	Takeshi IMANISHI		
					Unit	1646		
					Name			
Sheet	6	Teminos E	10	Attorney I	Docket Number	01834CIP/HG		
		OTHER PI	RIOR ART	- NON-PAT	TENT LITERAT	URE DOCUMENTS		
Examiner Initials <sup>1</sup>	Cite No.1					article, title of item, date, d/or country where published	T²	
			ANSEN, "Prote Y, 1995, 7, 7		ling of extracellu	lar matrix", <u>Current Opinion in</u>		
			-					
				ar and Cellula iews, 1995, 10	_	Insulin-Like Growth Factor I		
		hydrophoic s	substituent e	ffectively in	hibit influenza vi	ligonucleotides combined with a rus reproduction and synthesis 1990, 259, 327-330.		
					kylribonucleosiden 995, 78, 486–504.	und Eigenschaften deren		
		DELISSER et 1994, 15, 49		lar and funct	ional aspects of P	ECAM-1/CD31", <u>Immunology Today</u> ,		
		Tissue Destr		id Mice Infect	_	rthritis, and Inflammatory Burgdorferi" <u>, Int. J.</u>		
				lloproteinase: <u>sis</u> , 1994, 14	_	sion: The Contribution of		
HO et al., "Treatment of severe lichen planus with cyclosporine", <u>Dermatol.</u> , 1990, 22, 64-68.						osporine", <u>J. Am. Acad.</u>		
		activated Pr Factor Bindi	rotein Kinase	Kinase 1-inde luding Closel	ependent and Requi	r Activity by ras Is Mitogeres Multiple Transcription and AP-1 Sequences", <u>J. Biol.</u>		
Examiner					Date			

<sup>\*</sup> RXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $<sup>^{1}</sup>$  Unique citation designation number.  $^{2}$  Place a check here if English translation is attached.

+ PTO/SB/08B (08-00)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitu	te fo	r Form 1449A/PT		ion Number	10/054,300	
			Filing Da	ate	January 22, 2002	
		isclosure Applicant	First Na	med Inventor	Takeshi IMANISHI	
	10		Group Ar	t Unit	1646	
	`\	R 1 9 2002	Examiner	Name		
Sheet	7	10	Attorney	Docket Number	01834CIP/HG	
			ART - NON-PA	TENT LITERAT	URE DOCUMENTS	
Examiner Initials <sup>1</sup>	Cite No.1				article, title of item, date, ad/or country where published	T <sup>2</sup>
		Regulated by Plate 139, 219-228.	elet/Endothelial Ce		Endothelial Adhesion Molecules e (CD31)", <u>J. Cell Biol.</u> , 1997,	
		HAKUGAWA et al., Eosinophil Infilt: with Ovalbumin (O' OUWERKERK-MAHADEV. in Vivo: Selective Rat", J. Pharmaco. WAHLESTEDT et al. protect cortical: Nature, 1993, 363 DEMERS et al., "En acid (PNA)", Nucl. CHEN et al., "Syntacids Research, 1: SHEA et al., "Syntacids Research, 1: OBERHAUSER and WAG into liposomes and	"The Inhibitory Effration in Cutaneous (A)", J. Dermatol., AN et al., "Isoenzy e Inhibition of the L. Exp. Therapeut., "Antisense oligodineurons from excitor 260-263.  Thanced PCR amplificia Acids Research, thesis of oligodeox (295, 23, 2661-2668.)  Thesis, hybridization of the conjugates, Number (1968).	ect of Anti-Adhesic Late Phase Respons 1997, 24, 73-79.  me-Selective Inhibit Conjugation of S-2 1996, 276, 923-928 eoxynucleotides to toxity and reduce for cation of VNTR loculation o	on Molecule Antibodies on se in Balb/c Mice Sensitized  Ation of Glutathione Conjugation e-Bromoisovalerylurea in the state of the sensitized of the sensitized of the sensitized of the sensitive of the sensitive of lipident of lipident of the sensitive of lipident of l	
Examiner Signature				Date Considered		
	Considered					

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $<sup>^{1}</sup>$  Unique citation designation number.  $^{2}$  Place a check here if English translation is attached.

				1					
Substitu	Substitute for Form 1449A/PTO			Application	on Number	10/054,300			
				Filing Dat	te	January 22, 2002			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Name	ed Inventor	Takeshi IMANISHI			
	APR 1 9 2002				Unit	1646			
	, APP			Examiner 1	Name				
Sheet	8	Of 1	.0	Attorney I	Docket Number	01834CIP/HG			
		OTHER PRI	OR ART	- NON-PAT	TENT LITERAT	URE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No.1					article, title of item, date, d/or country where published	T²		
		SURZHYKOV and 1994, 13, 2283		"Novel 4'-Br	anched Nucleosides	", <u>Nucleosides &amp; Nucleotides</u> ,			
		1	_			on of the pharmacokinetic des, 1995, 14, 969-973.			
		REGEZI et al., Med. Oral Path				then planus", Oral Surq. Oral			
			gy", Pharma			in Kinase C and its Relevance tar, CRC Press, Boca Raton,			
		(92-kDa gelati	inase/colla	genase) to the		matrix metalloproteinase 9 type in transformed rat embryo			
			ls, PN3/SNS	and NaN/SNS2		the tetrodotoxin-insensitive chronic pain", <a href="Proc. Natl.">Proc. Natl.</a>			
			n of phosph	orothioate an		ssion in mice after systemic mucleotides", <u>Proc. Natl. Acad.</u>			
		RININSLAND et al., "Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells", <a href="Proc. Natl. Acad. Sci.">Proc. Natl. Acad. Sci.</a> , 1997, 94, 5854-5859.							
		activity as in	nhibitors o	f replication		des: Synthesis, properties, and ficiency virus in cell			
Examiner Signature					Date Considered	· · · · · · · · · · · · · · · · · · ·			

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Place a check here if English translation is attached.

+ PTO/SB/08B (08-00)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

				Υ		<del></del>	
Substitu	te fo	r Form 144	9A/PTO	Application	on Number	10/054,300	
				Filing Dat	te	January 22, 2002	
	INFORMATION DISCLOSURE STATEMENT BY PAPPLICANT			First Name	ed Inventor	Takeshi IMANISHI	
/				Group Art	Unit	1646	
	APR	1 9 2002		Examiner 1	Name		···-
Sheet	FAVT	of Of	10	Attorney 1	Docket Number	01834CIP/HG	
		OTHER P	RIOR ART	- NON-PA	TENT LITERAT	URE DOCUMENTS	
Examiner Initials <sup>1</sup>	Cite No.1					article, title of item, date, d/or country where published	T²
						nucleotides containing the three l. Sci., 1992, 89, 8631-8635.	
				ogy of Diseas 1, 1995, 73, 3		owth Factor-I Receptor",	;
		MILNER, "Ch	arles Darwin	and Associates, Ghostbusters", <u>Scientific American</u> , 1996, 275,			
1		BYNE, "The	Biological Ev	ridence Challe	nged", <u>Scientific</u>	<u>American</u> , May 1994, 50-55.	
					iety and Neuropept , 259, 528-531.	ide Y-Y1 Receptors by Antisense	
		Guanine, 5-	Methylcytosin	e, Thymine an	d Uracil Bicyclonu	of the Adenine, Cytosine, cleoside Monomers, tion", <u>Tetrahedron</u> , 1998, 54,	
		IYER et al., "A Novel Nucleoside Phosphoramidite Synthon Derived from 1R,2S- Ephedrine", Tetrahedron Asymmetry, 1995, 6, 1051-1054.  MANOHARAN et al., "Lipidic Nucleic Acids", Tetrahedron Letters, 1995, 36, 3651-3654.					
					, , , , , , , , , , , , , , , , , , , ,		
Examiner Signature					Date Considered		
		•			·		

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPBP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $<sup>^{1}</sup>$  Unique citation designation number.  $^{2}$  Place a check here if English translation is attached.

+ PTO/SB/08B (08-00)
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

			$\overline{}$
orm 1449A/PTO	Application Number	10/054,300	
	Filing Date	January 22, 2002	
INFORMATION DISCLOSURE STATEMENT BY ADPLICANT  APR 1 9 2002	First Named Inventor	Takeshi IMANISHI	
	Group Art Unit	1646	
	Examiner Name		
0f. 10	Attorney Docket Number	01834CIP/HG	0
THER PRIOR ART	- NON-PATENT LITERATU	RE DOCUMENTS	
			T²
logues with a fixed N	-type conformation, 2'-0,4'-C-me		
KOW et al., eds, The A	Merck Manual of Diagnosis and Th	nerapy, 15th Ed., Rahway, NJ,	
KOW et al., eds, <i>The i</i>	Merck Manual of Diagnosis and Th	nerapy, 15th Ed., Rahway, NJ,	
KOW et al., eds, <i>The I</i> 7, 2286-2292.	Merck Manual of Diagnosis and Th	nerapy, 15th Ed., Rahway, NJ,	
KOW et al., eds, <i>The 1</i> 7, 2301-2310.	Merck Manual of Diagnosis and Th	nerapy, 15th Ed., Rahway, NJ,	
	Date Considered		
	TCANT  1 9 2002  THER PRIOR ART  Include name of author page(s), volume-issue  KA et al., "Stability logues with a fixed N rahedron Letters, 199  KA et al., "Synthesis O,4'-C-methylene-5-me  KOW et al., eds, The 7, 2263-2277.  KOW et al., eds, The 7, 2286-2292.  KOW et al., eds, The 7, 2286-2292.  KOW et al., eds, The 7, 2301-2310.	First Named Inventor  Group Art Unit  Examiner Name  Attorney Docket Number  THER PRIOR ART - NON-PATENT LITERATU  Include name of author (in CAPITAL LETTERS), title of page(s), volume-issue number(s), publisher, city and KA et al., "Stability and structural features of the logues with a fixed N-type conformation, 2'-0,4'-C-me rahedron Letters, 1998, 39, 5401-5404.  KA et al., "Synthesis of a conformationally locked AZ 0,4'-C-methylene-5-methyluridine", Tetrahedron Letter KOW et al., eds, The Merck Manual of Diagnosis and Th. 7, 2263-2277.  KOW et al., eds, The Merck Manual of Diagnosis and Th. 7, 2283-2285.  KOW et al., eds, The Merck Manual of Diagnosis and Th. 7, 2286-2292.  KOW et al., eds, The Merck Manual of Diagnosis and Th. 7, 2301-2310.  ERT and MORRIS, "Antisense knockouts: molecular scalp nal transduction", Trends in Pharmacological Sciences	First Named Inventor  Group Art Unit  Group Art Unit  Examiner Name  Attorney Docket Number  O1834CIP/HG  THER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS  Include name of author (in CAPITAL LETTERS), title of article, title of item, date, page(s), volume-issue number(s), publisher, city and/or country where published  KA et al., "Stability and structural features of the duplexes containing nucleoside rahedron Letters, 1998, 39, 5401-5404.  KA et al., "Synthesis of a conformation, 2'-0,4'-C-methylenerionucleosides", archedron Letters, 1998, 39, 5401-5404.  KA et al., "Synthesis of a conformationally locked AZT analogue, 3'-azido-3'-deoxy-0,4'-C-methylene-5-methyluridine", Tetrahedron Letters, 1999, 40, 6465-6468.  KOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 7, 2263-2227.  KOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 7, 2283-2285.  KOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 7, 2286-2292.  KOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 7, 2286-2292.  KOW et al., eds, The Merck Manual of Diagnosis and Therapy, 15th Ed., Rahway, NJ, 7, 2301-2310.  ERT and MORRIS, "Antisense knockouts: molecular scalpels for the dissection of nal transduction", Trends in Pharmacological Sciences, 1994, 15, 250-254.

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 $<sup>^1</sup>$  Unique citation designation number.  $^2$  Place a check here if English translation is attached.